(Health and Medical Publishing Group (HMPG), 2008-04) Oliphant, C. E. M.; Young, T.; Araoyinbo, I.; Volmink, J.
Human immunodeficiency virus (HIV) damages the body’s
immune system, making secondary (or opportunistic)
infections more common. Treatment and prevention of such
infections is integral to the management of patients with HIV
infection. Co-trimoxazole is a prophylactic treatment that has a
wide range of action against common bacteria, parasites, fungi
and yeasts. As part of a minimum care package, UNAIDS/
WHO recommends co-trimoxazole prophylaxis for HIVinfected
adults with symptomatic disease (WHO stage II, III
or IV), or asymptomatic individuals with CD4 counts ≤500
cells/μl, and for all HIV-positive pregnant women after the
first trimester.1 Co-trimoxazole is also recommended for use in
children with proven HIV infection and infants exposed to HIV
(from 4 - 6 weeks of age until infection with HIV is ruled out).2
The object of this report is to summarise the effects of
co-trimoxazole prophylaxis on morbidity and mortality among
HIV-infected individuals.